Discovery of ligands for the human intestinal Di-/tripeptide transporter (hPEPT1) using a QSAR-assisted virtual screening strategy

ChemMedChem

Volumn 4, Issue 9, 2009, Pages 1439-1445

  Larsen, Simon Birksø ^a   Omkvist, Diana Højmark ^a   Brodin, Birger ^a   Nielsen, Carsten Uhd ^a   Steffansen, Bente ^a   Olsen, Lars ^a   Jørgensen, Flemming Steen ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

hPEPT1; Peptide transporters; Peptides; QSAR; Virtual screening

Indexed keywords

BENZOPHENONE DERIVATIVE; CARBON 14; GLYCINE; LIGAND; PEPTIDE TRANSPORTER 1;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; DATA BASE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

ANIMALS; BENZOPHENONES; CELL LINE; DATABASES, FACTUAL; DOGS; HUMANS; LIGANDS; PRINCIPAL COMPONENT ANALYSIS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SMALL MOLECULE LIBRARIES; SYMPORTERS;

EID: 69749098087     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200900145     Document Type: Article

References (28)

1. Y. J. Fei, Y. Kanai, S. Nussberger, V. Ganapathy, F. H. Leibach, M. F. Romero, S. K. Singh, W. F. Boron, M. A. Hediger, Nature 1994, 368, 563-566.
2. M. Brandsch, I. Knutter, E. Bosse-Doenecke, J. Pharm. Pharmacol. 2008, 60, 543-585.
3. M. Brandsch, I. Knutter, F. H. Leibach, Eur. J. Pharm. Sci. 2004, 21, 53-60.
4. i>15 mM should be considered with great caution and are not considered to be inhibitors/substrates; see reference [3].
5. A. Biegel, S. Gebauer, B. Hartrodt, M. Brandsch, K. Neubert, I. Thondorf, J. Med. Chem. 2005, 48, 4410-4419.
6. S. Gebauer, I. Knutter, B. Hartrodt, M. Brandsch, K. Neubert, I. Thondorf, J. Med. Chem. 2003, 46, 5725-5734.
7. R. D. Cramer, D. E. Patterson, J. D. Bunce, J. Am. Chem. Soc. 1988, 110, 5959-5967.
8. G. Klebe, U. Abraham, T. Mietzner, J. Med. Chem. 1994, 37, 4130-4146.
9. A. Hillebrecht, G. Klebe, J. Chem. Inf. Model. 2008, 48, 384-396.
10. S. B. Larsen, F. S. Jørgensen, L. Olsen, J. Chem. Inf. Model. 2008, 48, 233-241.
11. B. S. Vig, T. R. Stouch, J. K. Timoszyk, Y. Quan, D. A. Wall, R. L. Smith, T. N. Faria, J. Med. Chem. 2006, 49, 3636-3644.
12. B. Bretschneider, M. Brandsch, R. Neubert, Pharm. Res. 1999, 16, 55-61.
13. P. D. Bailey, C. A. R. Boyd, I. D. Collier, J. P. George, G. L. Kellett, D. Meredith, K. M. Morgan, R. Pettecrewa, R. A. Pricea, Chem. Commun. 2006, 323-325.
14. See, for example: M. Shen, C. Beguin, A. Golbraikh, J. P. Stables, H. Kohn, A. Tropsha, J. Med. Chem. 2004, 47, 2356-2364.
15. G. Cruciani, M. Pastor, W. Guba, Eur. J. Pharm. Sci. 2000, 11, S29-S39.
16. M. Pastor, G. Cruciani, I. Mclay, S. Pickett, S. Clementi, J. Med. Chem. 2000, 43, 3233-3243.
17. Molecular Operating Environment (MOE) v.2006.08, Chemical Computing Group Inc., Montreal QC (Canada).
18. PubChem (http://pubchem.ncbi.nlm.nih.gov/), accessed June 2, 2009.
19. J. J. Irwin, B. Shoichet, J. Chem. Inf. Model. 2005, 45, 177-182.
20. J. W. Godden, J. Bajorath, J. Chem. Inf. Model. 2006, 46, 1094-1097.
21. J. Kamphorst, L. Cucurull-Sanchez, B. Jones, QSAR Comb. Sci. 2007, 26, 220-226.
22. D. M. Matthews, Physiol. Rev. 1975, 55, 537-608.
23. S. Ekins, J. S. Johnston, P. Bahadduri, V. M. D'Souza, A. Ray, C. Chang, P. W. Swaan, Pharm. Res. 2005, 22, 512-517.
24. W. L. DeLano, The PyMOL Molecular Graphics System (2002), DeLano Scientific, Palo Alto, CA (USA).
25. CONCORD v.6.1.2, accessed via SYBYL from Tripos Associates Inc., St. Louis, MO (USA).
26. T. N. Faria, J. K. Timoszyk, T. R. Stouch, B. S. Vig, C. P. Landowski, G. L. Amidon, C. D. Weaver, D. A. Wall, R. L. Smith, Mol. Pharm. 2004, 1, 67-76.
27. S. A. Bravo, C. U. Nielsen, S. Frøkjær, B. Brodin, Mol. Pharm. 2005, 2, 98-108.
28. Y. Cheng, W. H. Prusoff, Biochem. Pharmacol. 1973, 22, 3099-3108.